LY2439821, An Anti-IL-17 Monoclonal Antibody, has been studied in Patients with Rheumatoid Arthritis in A Phase 2 Study

Mark C. Genovese and colleagues compared multiple subcutaneous doses of LY2439821 (3, 10, 30, 80, or 180 mg), an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: naȉve to biologic therapy or inadequate responders to tumor necrosis factor alpha inhibitors for the improvement of signs and symptoms of rheumatoid arthritis. The DAS28-CRP LSMEAN change from baseline showed a significant change even at the lowest level of LY2439821 tested (3 mg). The author saw an improvement of signs and symptoms of rheumatoid arthritis compared to placebo with a rapid onset of action.

[WED] 2591
A Phase 2 Study of Multiple Subcutaneous Doses of LY2439821, An Anti-IL-17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis in Two Populations: Naȉve to Biologic Therapy or Inadequate Responders to Tumor Necrosis Factor Alpha Inhibitors.
Mark C. Genovese1, Maria W. Greenwald2, Chul Soo Cho3, Alberto Berman4, Ling Jin5, Gregory Cameron6, Li Xie5, Daniel Braun5, Subhashis Banerjee5 and Laura Warner7.
1Stanford University, Palo Alto, CA, 2Desert Medical Advances, Palm Desert, CA, 3St Marys Hospital, Seoul, 4Hospital Padilla, Tucuman, Argentina, 5Eli Lilly and Company, Indianapolis, IN, 6Eli Lily and Company, Indianapolis, IN, 7i3 Statprobe, Indianapolis, INConclusion: LY significantly improved signs and symptoms of RA compared to PB with a rapid onset of action and a safety profile comparable to other biologic therapies with no unexpected safety concerns.